NIKKEI 225
37,786.89 -769.98 (-2.00%) HANG SENG
18,477.01 -344.15 (-1.83%) CRUDE OIL
79.12 -0.11 (-0.14%) GOLD FUTURES
2,333.90 -7.30 (-0.31%) DOW
38,441.54 -411.32 (-1.06%) Bitcoin GBP
53,302.24 -611.27 (-1.13%)
Merck & Co., Inc. (6MK.F)
| Previous close | 116.20 |
| Open | 115.60 |
| Bid | 116.60 x 100000 |
| Ask | 116.80 x 100000 |
| Day's range | 115.00 - 116.60 |
| 52-week range | 90.70 - 123.20 |
| Volume | |
| Avg. volume | 313 |
| Market cap | 295.326B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 140.48 |
| EPS (TTM) | 0.83 |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | 2.84 (2.45%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
Business WireFDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
RAHWAY, N.J., May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The FDA has set a Prescription Drug User Fee
Business WireMerck to Acquire EyeBio
RAHWAY, N.J. & NEW YORK, May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
ReutersMerck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Merck has said it's in the market for deals of up to around $15 billion as it plans ways to deal with a loss of revenue from its aging cancer immunotherapy Keytruda.
